重组人生长激素治疗特发性矮小症的疗效及对患儿生长发育的影响  

Efficacy of recombinant human growth hormone in the treatment of idiopathic short stature and its influence on the growth and development of children

作　　者：叶永清 严红 李知民 YE Yongqing;YAN Hong;LI Zhimin(Department of Child Health,Nanping Maternal and Child Health Hospital,Nanping,Fujian,353000,China)

机构地区：[1]南平市妇幼保健院儿童保健科,福建南平353000

出　　处：《当代医学》2023年第17期113-115,共3页Contemporary Medicine

摘　　要：目的探讨重组人生长激素(rhGH)治疗特发性矮小症的疗效及对患儿生长发育的影响。方法选取2019年3月至2020年3月本院内分泌科收治的76例特发性矮小症患儿作为研究对象,按照家属治疗意愿分为对照组(n=31)与观察组(n=45)。对照组进行强化营养指导干预,观察组在对照组基础上联合rhGH干预,比较两组体质量、身高、骨龄、生长速率(GV)、身高标准差分值(HtSDS)、骨代谢指标[骨钙素(OC)、骨碱性磷酸酶(BAP)]。结果观察组治疗后身高、体质量、GV均高于对照组,差异有统计学意义(P<0.05)。观察组HtSDS高于对照组,骨龄大于对照组,差异有统计学意义(P<0.05)。治疗前,两组OC、BAP水平比较差异无统计学意义;治疗后,两组OC、BAP水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。结论rhGH治疗特发性矮小症效果确切,可提高患儿骨代谢水平,促进患儿生长发育,值得临床推广应用。Objective To investigate the therapeutic efficacy of recombinant human growth hormone(rhGH)in the treatment of idiopathic short stature and its influence on the growth and development of children.Methods A total of 76 children with idiopathic short stature admitted to the Endocrinology department of our hospital from March 2019 to March 2020 were selected as the research subjects,and they were divided into the control group(n=31)and the observation group(n=45)according to the treatment wishes of their families.The control group was given intensive nutrition guidance intervention,and the observation group was combined with rhGH intervention on the basis of the control group,the body weight,height,bone age,growth velocity(GV),height standard deviation score(HtSDS),bone metabolism index(osteocalcin[OC],bone alkaline phosphatase[BAP])were compared between the two groups.Results After treatment,the height,weight and GV in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The HtSDS in the observation group was higher than that in the control group,and the bone age was higher than that in the control group,the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in OC and BAP levels between the two groups;after treatment,the levels of OC and BAP of the two groups were higher than those before treatment,and the observation group was higher than the control group,the differences were statistically significant(P<0.05).Conclusion rhGH is effective in the treatment of idiopathic short stature,it can improve the level of bone metabolism and promote the growth and development of children,it is worthy of clinical promotion application.

关 键 词：特发性矮小症 生长发育 重组人生长激素 

分 类 号：R725.8[医药卫生—儿科]